Volume 15, Number 7—July 2009
Dispatch
Lack of Macrolide Resistance in Chlamydia trachomatis after Mass Azithromycin Distributions for Trachoma
Kevin Cyrus Hong, Julius Schachter, Jeanne Moncada, Zhaoxia Zhou, Jenafir House, and Thomas M. Lietman
Table
Antimicrobial drug susceptibilities of Chlamydia trachomatis, Ethiopia*
| Treatment status | Serotype | Azithromycin† |
Doxycycline† |
|||
|---|---|---|---|---|---|---|
| MIC | MCC | MIC | MCC | |||
| 4 biannual | A/Har13 | 0.5 | 0.5 | 0.03 | 0.03 | |
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.03 | ||
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 | 0.25 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 |
0.5 |
0.5 |
0.03 |
0.03 |
||
| None | A/Har 13 | 0.5 | 0.5 | 0.03 | 0.03 | |
| A/Har 13 | 0.5 | 0.5 | 0.03 | 0.03 | ||
| A/Har 13 | 0.5 | 1 | 0.015 | 0.06 | ||
| Ba/Apache-2 | 0.25 | 0.25 | 0.03 | 0.03 | ||
*Samples taken in 2006, 18 months after 4 biannual treatments in 2003–2004. MCC, minimum chlamydicidal concentration.
†MIC and MCC values given in μg/mL.
Page created: November 08, 2010
Page updated: November 08, 2010
Page reviewed: November 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.